New tool makes gene regulation easier to study—and tweak

Leuven, 2 April 2026 - Understanding how genes are switched on and off in specific cell types remains one of biology’s central challenges. While AI has made major progress in decoding the regulatory logic of DNA, applying these approaches across datasets, tissues, and species has remained difficult. In a new Nature Methods paper, a research team led by Prof. Stein Aerts (VIB & KU Leuven) presents CREsted, a software package that enables both the analysis and design of gene regulatory elements in a systematic and scalable way.

Enhancers are gene regulatory elements—short DNA sequences that control when and where genes are active. Deep learning models can help decode this “regulatory code”, but existing approaches are often tailored to one dataset or one task, making them hard to reuse or extend.

To address this, Prof. Stein Aerts and his team developed CREsted, a new framework that turns enhancer modeling from a collection of one-off analyses into a more systematic and reusable workflow.

“We wanted to move beyond one-off models,” says Niklas Kempynck, PhD student in the Aerts lab. “CREsted allows researchers to systematically study enhancer logic across biological systems, starting from cell-by-cell maps of accessible regulatory DNA and going all the way to sequence design.”

CREsted brings together several steps that are usually handled separately: preprocessing, model training, interpretation, and synthetic enhancer design. It is also built to fit into existing single-cell analysis workflows, making it easier for researchers to adopt and use.

Prof. Stein Aerts, Dr. Seppe De Winter, and Niklas Kempynck
“With CREsted, we give researchers a complete workflow,” says Dr. Seppe De Winter, who shares first authorship with Kempynck. “You can train deep learning models on chromatin accessibility data, interpret which regulatory features they capture, and then use those models to design new DNA sequences with predicted cell-type-specific activity.”

To show its versatility, the team applied CREsted to multiple systems, including mouse brain tissue, human immune cells, cancer cell states, and zebrafish development. Across these settings, the framework identified regulatory patterns, predicted enhancer activity, and enabled the design of synthetic enhancers, which were validated in vivo in zebrafish.

For Prof. Stein Aerts, Scientific Director of VIB.AI, the strength of CREsted lies in making a powerful development more coherent and reusable.

“CREsted makes it much easier to train, interpret, and compare enhancer models across datasets,” he says. “That is important if we want these approaches to become broadly useful, not just for understanding regulatory DNA, but also for designing and testing new sequences in a systematic way.”

Taken together, the work shows how AI can help move the field from describing regulatory DNA to actively exploring and designing it. With applications ranging from fundamental biology to biotechnology and medicine, CREsted lays the groundwork for more systematic and programmable control of gene regulation.


Publication

CREsted: modeling genomic and synthetic cell type-specific enhancers across tissues and species. Kempynck, De Winter et al. Nature Methods, 2026. DOI: https://doi.org/10.1038/s41592-026-03057-2

Funding

This research was funded in part by Aligning Science Across Parkinson’s through the Michael J. Fox Foundation for Parkinson’s Research (MJFF); the European Research Council, the Chan-Zuckerberg Initiative, the Research Foundation Flanders - FWO, and the Foundation Against Cancer. For all funders, see the paper’s acknowledgements.

 

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be